You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恩華藥業(002262.SZ)2020年度淨利潤升9.88%至7.29億元 擬10派1元
格隆匯 03-11 20:06

格隆匯 3 月 11日丨恩華藥業(002262.SZ)發佈2020年年度報吿,實現營業收入33.61億元,同比下降18.99%;歸屬於上市公司股東的淨利潤7.29億元,同比增長9.88%;歸屬於上市公司股東的扣除非經常性損益的淨利潤7.10億元,同比增長17.86%;基本每股收益0.72元,擬每10股派發現金紅利1元(含税)。經營活動產生的現金流量淨額12.48億元,同比增長307.99%。

公司主要從事中樞神經類藥物及心腦血管類藥物的研發,實施了創仿分設,創仿並重。報吿期內,公司投入科研經費245,863,036.38元,比上年度增長了30.10%,在研科研項目70多項。開展一致性評價項目18個,其中鹽酸丁螺環酮片(10mg15mg)及咪達唑侖注射液(10ml50mg) 2個項目均為增加新規格所做的一致性評價,其餘16個項目一致性評價的研發進展情況詳見2020年年度報吿全文第三節報吿期內公司從事的主要業務的相關內容。仿製藥重點在研項目39個,其中有20個項目處於研發的不同階段或處於研發保密階段,其餘19個項目的研發進展情況詳見2020年年度報吿全文第三節報吿期內公司從事的主要業務的相關內容。在研創新藥項目有20多項,其中16個項目的研發進展情況詳見2020年年度報吿全文第三節報吿期內公司從事的主要業務的相關內容,其餘研發項目尚處於研發的不同階段。

報吿期內申請發明專利65件,PCT專利申請5件,獲得授權發明專利30件。其中:1項專利獲首屆徐州市專利金獎,另有1項專利獲優秀獎。

報吿期內,恩華連鎖按照立足徐州,做區域龍頭發展思路,實行區域聚焦戰略,2020年新增門店10家。截至報吿期末,共有83家門店(其中:醫保門店74家,特保藥店3家,市縣互認藥店25家)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account